![]() The Santa Monica facility has approximately 18,000 square feet and will provide space for clinical manufacturing, research and development, and offices upon completion. In addition, Kite plans to continue to utilize its contract manufacturer to support clinical trials of eACT™ based product candidates. We also expect the facilities to support clinical trials and potential commercialization of our other eACT™ based product candidates, including both chimeric antigen receptor (CAR) and T cell receptor (TCR) based product candidates." "We are committed to the rapid advancement of KTE-C19, which has the potential to address the significant, unmet needs of patients with aggressive, refractory B cell lymphomas and leukemias," said Arie Belldegrun, M.D., FACS, Kite Pharma's President and Chief Executive Officer. "We are initiating pivotal studies for KTE-C19 in multiple indications and believe our new facilities will help ensure the timely completion of these studies as well as our commercial launch. The two facilities will not only support the planned clinical trials of Kite's product candidates, but also will prepare Kite for the commercial launch and supply of its lead product candidate, KTE-C19, anticipated in 2017. ![]() Kite also recently secured a lease for a clinical manufacturing facility in Santa Monica, California. 19, 2015 (GLOBE NEWSWIRE) - Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that it has entered into a lease agreement for a commercial manufacturing facility in El Segundo, California, which is adjacent to Los Angeles International Airport. Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products
0 Comments
Leave a Reply. |